THE US Food and Drug
Administration has warned that
that surgical placement of mesh
through the vagina to repair pelvic
organ prolapse (POP) may expose
patients to greater risk than other
surgical options.
In 2008 the FDA issued a warning
about adverse events related to
mesh placement, however since
then it has seen the number of
adverse events increase fivefold.
The most common side effects
include protruding of tissue, pain,
infection and bleeding.
As such, the FDA has asked
health care providers to recognise,
that in most cases POP can be
treated successfully without
surgery, and that patients continue
with routine check-ups and followup
care after surgery.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jul 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jul 11
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.